Michael Tomsicek Net Worth

The estimated Net Worth of Michael John Tomsicek is at least $4.73 Milhão dollars as of 19 October 2022. Mr. Tomsicek owns over 15,000 units of CRISPR Therapeutics AG stock worth over $681,600 and over the last 9 years he sold CRSP stock worth over $0. In addition, he makes $4,043,990 as Chief Financial Officer at CRISPR Therapeutics AG.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Tomsicek CRSP stock SEC Form 4 insiders trading

Michael has made over 5 trades of the CRISPR Therapeutics AG stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 15,000 units of CRSP stock worth $79,800 on 19 October 2022.

The largest trade he's ever made was exercising 25,000 units of CRISPR Therapeutics AG stock on 6 August 2021 worth over $443,750. On average, Michael trades about 2,906 units every 35 days since 2015. As of 19 October 2022 he still owns at least 15,000 units of CRISPR Therapeutics AG stock.

You can see the complete history of Mr. Tomsicek stock trades at the bottom of the page.

Michael Tomsicek biography

Michael John Tomsicek serves as Chief Financial Officer of the Company. Prior to joining our company, Prior to joining our company, Mr. Tomsicek served as Chief Financial Officer of Abiomed, a publicly-traded provider of medical devices, from July 2015 to August 2017. Before that, Mr. Tomsicek was Senior Vice President, Chief Financial Officer at Cubist Pharmaceuticals. He was at Cubist from August 2010 to January 2015 (through its sale to Merck) and held a series of roles of increasing responsibility leading finance, investor relations and strategic sourcing through a period of dynamic growth at the company. Prior to Cubist, Mr. Tomsicek spent nearly eight years at General Electric Healthcare, as finance manager in global operations, and then as chief financial officer of its ultrasound business. Mr. Tomsicek holds a BS in engineering and an MBA, both from the University of Wisconsin.

What is the salary of Michael Tomsicek?

As the Chief Financial Officer of CRISPR Therapeutics AG, the total compensation of Michael Tomsicek at CRISPR Therapeutics AG is $4,043,990. There are 4 executives at CRISPR Therapeutics AG getting paid more, with Samarth Kulkarni having the highest compensation of $16,265,700.

How old is Michael Tomsicek?

Michael Tomsicek is 54, he's been the Chief Financial Officer of CRISPR Therapeutics AG since 2017. There are 3 older and 9 younger executives at CRISPR Therapeutics AG. The oldest executive at CRISPR Therapeutics AG is Katherine High, 68, who is the Independent Director.

What's Michael Tomsicek's mailing address?

Michael's mailing address filed with the SEC is C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTREAL, A8, H4M 2X6.

Insiders trading at CRISPR Therapeutics AG

Over the last 8 years, insiders at CRISPR Therapeutics AG have traded over $284,003,967 worth of CRISPR Therapeutics AG stock and bought 3,347,446 units worth $53,410,590 . The most active insiders traders include Plc Gsk, Ali Behbahani, eCorp /De/ Celgene. On average, CRISPR Therapeutics AG executives and independent directors trade stock every 13 days with the average trade being worth of $2,405,548. The most recent stock trade was executed by Julianne Bruno on 20 June 2024, trading 7,000 units of CRSP stock currently worth $318,080.

What does CRISPR Therapeutics AG do?

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Complete history of Mr. Tomsicek stock trades at Abiomed, CRISPR Therapeutics AG, eMilestone Pharmaceuticals Inc

CRISPR Therapeutics AG executives and stock owners

CRISPR Therapeutics AG executives and other stock owners filed with the SEC include:

• Samarth Kulkarni,
  Chief Executive Officer, Director
• Lawrence Klein,
  Chief Operating Officer, Chief Business Officer
• Tony Ho,
  Executive Vice President - Research and Development
• James Kasinger,
  General Counsel, Secretary
• Michael Tomsicek,
  Chief Financial Officer
• Dr. Samarth Kulkarni,
  CEO & Director
• Dr. Lawrence Otto Klein Ph.D.,
  Chief Operating Officer
• James R. Kasinger,
  Gen. Counsel & Sec.
• Rodger Novak,
  Chairman of the Board, President, Co-Founder
• Dr. Rodger Novak M.D.,
  Founder, Chairman & Pres
• Susan Kim,
  IR Contact Officer
• Katherine High,
  Independent Director
• John Greene,
  Independent Director
• Simeon George,
  Independent Director
• Bradley Bolzon,
  Independent Director
• Ali Behbahani,
  Independent Director
• Dr. Daniel G. Anderson Ph.D.,
  Scientific Founder & Advisory Board Member
• Dr. Matthew Porteus M.D., Ph.D.,
  Scientific Founder & Advisory Board Member
• Dr. Chad Cowan Ph.D.,
  Scientific Founder
• Dr. Craig C. Mello Ph.D.,
  Scientific Founder & Advisory Board Member
• Dr. Emmanuelle Marie Charpentier,
  Co-Founder & Scientific Advisory Board Member
• Shaun Foy,
  Founder
• Aktiengesellschaft Bayer Gl...,
  
• Tyler Dylan Hyde,
  Chief Legal Officer
• Pablo J Cagnoni,
  Director
• Venture Capital Iv, L.P.Ver...,
  
• Harbor Master Investors (Ca...,
  10% owner
• Kurt Von Emster,
  Director
• Sven Ante Lundberg,
  Chief Scientific Officer
• Corp /De/ Celgene,
  10% owner
• Kala Subramanian,
  See Remarks
• Thomas Woiwode,
  Director
• N Anthony Coles,
  Director
• Plc Gsk,
  10% owner
• Pharmaceuticals (Europe) Lt...,
  
• Venture Capital Iv, L.P.Ver...,
  
• Julianne Bruno,
  Chief Operating Officer
• Brendan Smith,
  Chief Financial Officer
• Venture Capital Iv, L.P.Ver...,
  
• Venture Capital V, L.P.Vers...,
  
• Naimish Patel,
  Chief Medical Officer
• Harold Edward Fleming,
  
• Maria Fardis,
  
• Sandesh Mahatme,
  
• Douglas A Treco,
  
• Christian Rommel,
  
• Phuong Khanh Morrow,
  Chief Medical Officer
• Raju Prasad,
  Chief Financial Officer